MarginsXMarginsX
Home › Markets › Health Care › VTVT

vTv Therapeutics Inc. (VTVT)

VTVT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$17.69
-10.16% on the day
Market cap
$71.0M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$27.0M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1641489/000164148926000010/0001641489-26-000010-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerVTVT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001641489
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$27.0M
Operating income-$32.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$88.9M
Total assets$89.9M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
42.6 months
$77.2M cash at September 30, 2026
Share count, 1 year
+1.9%
2025-10-31 to 2026-11-05
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$77.2M cash; operating cash flow -$5.4M a quarter.Report 2026-09-30
Shares outstanding4,011,557 (2026-11-05); 3,938,259 a year earlier.Cover page 2026-11-05
Reverse splits, 3 years1; latest 1-for-40 on 2023-11-21Source 2023-11-21
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Detroit, Michigan, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$11.6M-$10.2M$77.2MNo debt tags$36.8M10-Q 2026-11-05
Q2 2026
2026-06-30
$0-$13.1M-$11.4M$86.6MNo debt tags$36.8M10-Q 2026-08-06
Q1 2026
2026-03-31
$36.8M$24.1M$9.2M$98.1MNo debt tags$36.8M10-Q 2026-05-13
Q4 2025
2025-12-31
$0-$7.1M-$9.3M$88.9MNo debt tags$010-K 2026-03-10
Q3 2025
2025-09-30
$0-$8.7M-$5.2M$98.5M$328K$17K10-Q 2026-11-05
Q2 2025
2025-06-30
$0-$6.0M-$5.1M$25.9MNo debt tags$17K10-Q 2026-08-06
Q1 2025
2025-03-31
$0-$5.1M-$5.7M$31.1MNo debt tags$17K10-Q 2026-05-13
Q4 2024
2024-12-31
$17K-$3.6M-$4.8M$36.7M$0$1.0M10-K 2026-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B22026-05-13
Latest annual report10-K2026-03-10
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-06-10

Source: SEC EDGAR submissions feed, 603 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.4%
1 month-30.3%
3 months-36.2%
Year to date-50.8%
1 year-37.0%
From 52-week high-53.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
COYACoya Therapeutics Inc.$3.00-4.15%$70.4M
CRBPCorbus Pharmaceuticals Holdings Inc.$3.38-0.44%$69.5M
TLSATiziana Life Sciences Ltd. Common Shares$0.5762+1.11%$73.3M
MNOVMedicinova Inc$1.34-3.94%$68.7M
KALAKALA BIO Inc.$3.83-8.02%$74.1M
ZYBTZhengye Biotechnology Holding Limited$1.43-4.67%$67.8M
TENXTenax Therapeutics Inc.$1.48-8.64%$67.4M
GOSSGossamer Bio Inc.$10.98+0.09%$67.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier